Clinical trial · Interventional
A Study of LY573636-sodium in Patients With Metastatic Breast Cancer
Phase 2 Evaluation of a Once Every 28 Days Dosing Regimen for LY573636-sodium in Patients With Metastatic Breast Cancer
NCT00992225CI-TRIAL-00033787completedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary purpose of this study is to determine the objective response rate (complete and partial response) for patients who receive LY573636-sodium for metastatic breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| LY573636-sodium | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- LY573636-sodium
- interventionNames
- Drug: LY573636-sodium
Primary outcomes (1)
- measure
- Percentage of Participants With an Objective Overall Response
- timeFrame
- Baseline to measured progressive disease or death from any cause up to 12 months
- description
- Objective overall response is complete response (CR) + partial response (PR), as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST) guidelines. CR is disappearance of all target and non-target lesions; PR is ≥30% decrease in sum of longest diameter of target lesions. It is calculated as a total number of participants with CR or PR divided by the total number of participants treated multiplied by 100.
Secondary outcomes (6)
- measure
- Progression-free Survival
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Received at least 2 or more prior chemotherapy regimens for metastatic breast cancer. * Have discontinued all previous therapies for cancer, including chemotherapy, radiotherapy, cancer-related hormonal therapy, or other investigational therapy for at least 4 weeks. Patients who have received whole-brain radiation must wait 90 days. Exclusion Criteria: * Serious pre-existing medical condition. * Have active central nervous system or leptomeningeal metastasis. * Current hematologic malignancies, acute or chronic leukemia. * Receiving Warfarin (Coumadin). * Have a history of radiation therapy involving more than 25% of the bone marrow.
References
Publications (0)
Data not yet available
No reference posted for this study.